Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
TRVN 
Trevena Inc (TRVN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/14/2025: TRVN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $5
1 Year Target Price $5
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -1.05% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 0.01M USD | Price to earnings Ratio - | 1Y Target Price 5 |
Price to earnings Ratio - | 1Y Target Price 5 | ||
Volume (30-day avg) 1 | Beta 0.63 | 52 Weeks Range 0.00 - 2.35 | Updated Date 10/17/2025 |
52 Weeks Range 0.00 - 2.35 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -48.89 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1970.67% |
Management Effectiveness
Return on Assets (TTM) -62.39% | Return on Equity (TTM) -1014.58% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 24112365 | Price to Sales(TTM) 0.02 |
Enterprise Value 24112365 | Price to Sales(TTM) 0.02 | ||
Enterprise Value to Revenue 44.16 | Enterprise Value to EBITDA 0.21 | Shares Outstanding 863788 | Shares Floating 858683 |
Shares Outstanding 863788 | Shares Floating 858683 | ||
Percent Insiders 0.48 | Percent Institutions 9.98 |
Upturn AI SWOT
Trevena Inc
Company Overview
History and Background
Trevena Inc. is a biopharmaceutical company focused on developing and commercializing novel medicines for central nervous system (CNS) disorders. Founded in 2007, Trevena's initial focus was on biased ligands targeting G protein-coupled receptors (GPCRs).
Core Business Areas
- Pain Management: Trevena develops and commercializes therapies for acute and chronic pain management.
- Central Nervous System (CNS) Disorders: The company is focused on developing new and innovative treatments for CNS disorders. The Pipeline include Pain, Neurology and Pulmonary areas.
Leadership and Structure
Remi Barbier is the current President and CEO. The company has a typical biopharmaceutical organizational structure with departments for research and development, clinical operations, commercial, and finance.
Top Products and Market Share
Key Offerings
- OLINVYK (oliceridine): OLINVYK is an IV opioid analgesic for the management of moderate to severe acute pain in adults. Trevena partners with different companies to commercialize the products, so revenue is dependent on the terms. Competitors include other opioid analgesics like morphine, fentanyl, and hydromorphone from companies like Pfizer (PFE) and Johnson & Johnson (JNJ).
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The acute pain management market is dominated by generic opioids.
Positioning
Trevena is positioned as an innovator in the pain management market with its biased ligand technology, aiming to develop safer and more effective pain relievers. However, competing with entrenched generic products is a challenge.
Total Addressable Market (TAM)
The acute pain management market is estimated to be billions of dollars annually. Trevena aims to capture a portion of this market with OLINVYK and future products.
Upturn SWOT Analysis
Strengths
- Novel biased ligand technology
- OLINVYK FDA approval
- Experienced leadership team
- Partnerships for commercialization
Weaknesses
- Limited commercial infrastructure
- Dependence on partnerships
- Financial losses and potential need for additional funding
- OLINVYK sales are low
Opportunities
- Expansion of OLINVYK indications
- Development of new biased ligand therapies
- Strategic collaborations and licensing agreements
- Address underserved patient populations
- Leveraging AI for faster drug discovery
Threats
- Competition from generic opioids
- Regulatory hurdles and delays
- Patent challenges
- Changing healthcare landscape
- Slow adoption of new opioid therapies
Competitors and Market Share
Key Competitors
- PFE
- JNJ
- Endo International (ENDP)
- Mallinckrodt (MNK)
Competitive Landscape
Trevena has a technological advantage with its biased ligand platform. Its challenges include competing with large pharmaceutical companies and establishing a strong commercial presence.
Growth Trajectory and Initiatives
Historical Growth: Growth has been variable, dependent on OLINVYK launch and partnerships.
Future Projections: Future growth depends on expanding OLINVYK market share and the success of pipeline products in clinical development. Analyst projections are contingent on these factors.
Recent Initiatives: Focus on commercializing OLINVYK, advancing pipeline programs, and exploring strategic partnerships.
Summary
Trevena is a biopharmaceutical company with a novel technology and an approved product, OLINVYK, but faces challenges with commercialization and profitability. Success hinges on expanding OLINVYK's market share and progressing its pipeline. The company needs to secure funding and manage competition from generic opioids. The long term goals need to be more established to gain traction in the market place.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
- Press Releases
Disclaimers:
The information provided is for informational purposes only and should not be construed as financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Trevena Inc
Exchange NASDAQ | Headquaters Chesterbrook, PA, United States | ||
IPO Launch date 2014-01-31 | President, CEO & Chairman Ms. Carrie L. Bourdow | ||
Sector Healthcare | Industry Biotechnology | Full time employees 23 | Website https://www.trevena.com |
Full time employees 23 | Website https://www.trevena.com | ||
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV734, a small molecule G protein biased ligand of the MOR, which has completed phase I studies for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.